tbuckley/cabot-search huggingface dataset:
THU0268 Tooth Loss is A Good Indicator for Periodontitis- Evaluation of A Patient Reported Periodontitis Score: Table 1.
Authors: J. Callhoff, G. Westhoff, M. Chubrieva, T. Dietrich, G. Schett, A. Zink
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The relationship between periodontitis (PD) and rheumatoid arthritis (RA) is well established but there is a lack of (large observational studies including) validated measurements of PD. <h3>Objectives</h3> To evaluate a patient reported PD-module that can be used to investigate the PD-status in large epidemiological studies. <h3>Methods</h3> For 353 patients from an early arthritis cohort (&lt;6 months symptom duration) patient-reported PD and dentists9 assessments of PD status were available for analysis. 232 patients had further independent evaluation of their PD status using radiographs obtained from their dentists. Patient reports included 12 items in total. Assessments by the patients9 dentists and an independent evaluation of radiographs were treated as gold standard with possible outcomes: no, mild, moderate or severe PD. Relevant patient-reported items were chosen using factor analysis, age was included as a covariate. Sensitivity, specificity and AUC were calculated for all 3 possible allocations "no" vs. "mild, moderate or severe" PD, "no or mild" vs. "moderate or severe" PD and "no, mild or moderate" vs. "severe" PD. <h3>Results</h3> Patients had a mean age of 56 years and a mean number of teeth of 19. According to dentist assessment, 30% had no, 34% mild, 26% moderate and 10% severe PD. Patient-reported items included in the PD-score were number of teeth, receding of jaw bone, presence of gum pockets/loose teeth/receding gums and extraction of teeth because of gum pockets. The factor analysis resulted in the same sample of items no matter which gold standard was used. Choosing the cutoff that optimized sensitivity and specificity simultaneously, the score was used to determine patient9s PD-status. With dentist9s assessment as gold standard, severe PD could be identified very well while considering the evaluation using radiographs patients with no PD could be identified best. For both assessments of PD, number of teeth alone was also a good predictor with AUCs only slightly lower than those for the six item score. <h3>Conclusions</h3> With good sensitivity and specificity for the detection of any vs. no PD the patient reported score is a helpful instrument. We recommend using it to further investigate the relationship between PD and clinical parameters of RA. <h3>Acknowledgements</h3> CAPEA was supported by an unconditional grant from Pfizer. The periodontitis project was supported by the German League of Rheumatology. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1488
Graves Disease Mimicking Solitary Autonomous Nodule at Scintigraphy
Authors: Suemi Marui, Gustavo Akerman Augusto, Tomoco Watanabe
Journal: Clinical Nuclear Medicine (2012)

A 21-year-old woman presented with Graves disease (GD), with high TSH-receptor antibody titers and mild diffuse goiter. Radioiodine therapy was indicated. Pretreatment scintigraphy revealed an unexpected autonomous nodule in the left lobe, not observed on ultrasound (homogenous goiter). After 3 months of successful radioiodine treatment, scintigraphy showed diffuse uptake in previously not visualized parenchyma. After 1 year, GD recurred. A new scintigraphy showed increased uptake in the whole gland, except in the previously hot left lobe. The follow-up confirmed the involvement of all gland, common to GD. We speculated that TRab could act only in focal thyroid tissue.
Abstract 1433: TC21/R-Ras2 is a critical mediator of the Nf1 oncogenic switch
Authors: Deanna M. Patmore, Sara Welch, Patricia Fulkerson, Jianqiang Wu, Kwangmin Choi, David Eaves, Jennifer Kordich, Margaret H. Collins, Timothy P. Cripe, Nancy Ratner
Journal: Cancer Research (2012)

Abstract The TC21/R-Ras2 protein is an oncogenic member of the Ras family. Ras proteins act as binary switches which are ‘active’ when bound to GTP and ‘inactive’ when bound to GDP. GTPase activating proteins (GAPs) accelerate the hydrolysis from Ras-GTP to Ras-GDP. This Ras-related GTPase TC21 has transforming capabilities similar to H, N and K-Ras. Activated alleles of TC21 transform epithelial and fibroblast cell lines and induce tumors in vivo. To explore the role of TC21 in cancer we used a model of Ras activation driven by loss of the NF1 tumor suppressor protein, a GAP for all Ras proteins including TC21. Thus loss of NF1 predicts increased levels of activated TC21/R-Ras2. NF1 loss in Schwann cells of the peripheral nervous system causes benign tumors known as neurofibromas. Neurofibromas can transform to sarcomas known as malignant peripheral nerve sheath tumors (MPNSTs). We found that TC21 loss delayed benign neurofibroma formation in Nf1fl/fl;DhhCre mice. Nf1 loss increased mRNA encoding the cytokine transforming growth factor-beta (TGF-β) and rendered Schwann cell progenitors insensitive to TGF-β; these phenotypes could be rescued by the Ras-related protein TC21/R-Ras2 and were mediated through TGF-β receptors. Conversely, growth of Nf1;Trp53 brain tumors and NF1−/− MPNST sarcomas were accelerated by TC21 loss. MPNST from Nf1;Trp53 mice and NF1−/− MPNST xenografts had increased levels of mRNA encoding TGF- ≤ ligands, and blocking TGF- ≤ decreased sarcoma size induced by shTC21. In benign and malignant tumors an AKT-dependent pathway regulated TGF- ≤ expression. Indicating relevance to human tumorigenesis, global gene expression analyses demonstrated increases in expression of TGF- ≤ ligands and decreases in TGF- ≤ receptors in human neurofibromas and MPNSTs. Thus, we identify critical roles for TC21 in regulation of TGF- ≤ expression. The results are important because TGF- ≤ acts as a tumor suppressor in numerous types of benign tumors and is also known for its oncogenic role in cellular transformation and tumor progression. While it has been known that Ras proteins are involved in TGF- ≤ mediated tumor suppression and oncogenesis, integration between the pathways is incompletely understood, especially in vivo. The study demonstrates that TC21 can be a major regulator of the duality of TGF- ≤ effects on tumorigenesis in vivo. This work was supported by a grant to NR (NIH P50NS057531-03). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1433. doi:1538-7445.AM2012-1433
The value of mammography vs. physical examination in detecting a recurrent breast cancer in women with a previous diagnosis of breast cancer.
Authors: NY Elmadhun, CA Finlayson
Journal: Cancer Research (2009)

Abstract Abstract #5014 Background: The value of mammography in detecting early breast cancer has been firmly established, however the benefit of mammography in detecting recurrent breast cancer has not been clearly elucidated. The purpose of this study is to determine the value of mammography versus physical examination in detecting a recurrent breast cancer in women with a previous diagnosis of breast cancer.&amp;#x2028; Methods: This is an IRB approved retrospective chart review. Fifty-eight patients were identified from our institution's Breast Center tumor registry who were diagnosed with stage I-II breast cancer from 1973-2006 and who subsequently developed a locoregional recurrence. The method of detection of the initial breast cancer was recorded and compared to the method of detection of the recurrent breast cancer.&amp;#x2028; Results: The mean age at the original diagnosis was 47 years (range 29-89 years). The mean time to recurrent breast cancer or second primary was 38 months (range 6-173 months). Seventeen patients (29%) were initially diagnosed with breast cancer by screening mammography. Of those 17, 3 (18%) were diagnosed with a recurrent breast cancer by mammography, and the remaining 14 by physical exam. Among the 14 patients that presented initially with a palpable breast mass and positive mammogram, 3 (21%) had recurrent breast cancer detected by mammography. Thirty-four patients (59%) initially presented with a palpable mass. Nineteen of these patients had mammograms, 5 did not have mammography, and 8 were unknown whether imaging was done. Of those 19 that had mammography, 14 were positive and 5 were negative. The 5 patients with palpable masses and negative mammograms all had mastectomies initially and their locoregional recurrence was detected by physical exam. Forty-nine patients (84%) had a clinical finding leading to the diagnosis of recurrent breast cancer and seven (12%) had recurrence identified by mammography. Two patients had unknown method of detection of recurrence. The clinical recurrences were identified in the axilla (53.4%), chest wall (12%), supraclavicular fossa (8.6%), breast (3.4%), and skin (3.4%).&amp;#x2028; Conclusions: One-third of patients with a recurrent breast cancer had their initial cancer identified by mammography but only 12% had their recurrence identified by mammography. Fifty-nine percent of patients were initially diagnosed by physical examination and 84% of recurrence was diagnosed with physical examination. Patients whose initial cancer was visible on mammogram are likely to have a recurrence also visible on mammogram. Though mammography is useful in detecting the first early stage breast cancer, most patients present with a clinical finding when they present with the recurrent breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5014.
Mutational Activation of the K-<i>ras</i>Oncogene
Authors: Sjoerd Rodenhuis, Marcus L. van de Wetering, Wolter J. Mooi, Siegina G. Evers, Nico van Zandwijk, Johannes L. Bos
Journal: New England Journal of Medicine (1987)

To define the role of cellular oncogenes in human cancers, we studied the prevalence of mutational activation of ras oncogenes in untreated non-small-cell lung cancer. Genomic DNA was extracted from 39 tumor specimens obtained by thoracotomy and was examined for activating point mutations in codons 12, 13, and 61 of the H-ras, K-ras, and N-ras genes. A novel, highly sensitive assay based on oligonucleotide hybridization following an in vitro amplification step was employed. The K-ras gene was found to be activated by point mutations in codon 12 in 5 of 10 adenocarcinomas. Two of these tumors were less than 2 cm in size and had not metastasized. No ras gene mutations were observed in 15 squamous-cell carcinomas, 10 large-cell carcinomas, 1 carcinoid, 2 metastatic adenocarcinomas from primary tumors outside the lung, and 1 small-cell carcinoma. An approximately 20-fold amplification of the unmutated K-ras gene was observed in a tumor that proved to be a solitary lung metastasis of a rectal carcinoma. We conclude that mutational K-ras activation may be an important early event in the pathogenesis of adenocarcinoma of the lung but that amplification of ras genes or mutational activation of H-ras or N-ras does not play a major part in non-small-cell lung cancer.
Cytogenetic Analysis of Melanocytes From Premalignant Nevi and Melanomas
Authors: J. M. Cowan, R. Halaban, U. Francka
Journal: JNCI Journal of the National Cancer Institute (1988)

Doxorubicin (DXR) conjugated to a monoclonal antibody (MAb), 9.2.27, which recognizes a human melanoma-associated proteoglycan, effectively suppresses the growth of human melanoma xenografts and prolongs the life span of tumor-bearing athymk nude (nulnu) mice. We have investigated further the mechanism(s) of this in viva antitu-mor activity. Our results indicate that following iv injection, the DXR-MAb 9.2.27 conjugate is cleared from the circulation with typical Diphasic kinetics, similar to the clearance process of the unconjugated MAb 9.2.27. In contrast, less than 10% of injected dose per milliliter of blood is found in the circulation at any given time after ip injection. Toxicity studies further indicate that DXR-MAb 9.2.27 conjugate is less toxic in vivo than the freely administered DXR, which is known to cause considerable cardiotoxic effects. Direct autoradiography demonstrates that the DXR-MAb 9.2.27 conjugate binds specifically to the tissue sections derived from a human melanoma xenograft of a nude mouse. A critical evaluation is given of the relevance of these findings and their impact on the design of future strategies for the immunochemotherapy of malignant melanoma. [J Natl Cancer Inst 1988;80:l154–1159]
PREVALENCE AND CHARACTERISTICS OF HEALED PLAQUES IN PATIENTS WITH SYMPTOMATIC CORONARY ARTERY DISEASE ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY AND INTRAVASCULAR ULTRASOUND
Authors: Haibo Jia, Sining Hu, Chong-Jin Kim, So-Yeon Choi, Jinwei Tian, Rocco Vergallo, Daniel Ong, Aaron D. Aguirre, Zhao Wang, Shiro Uemura, Tsunenari Soeda, Yoshiyasu Minami, Lei Gao, Hang Lee, Shaosong Zhang, Jingbo Hou, Jingbo Hou, Bo Yu, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2015)
AB1146-HPR Assessment of Health Problems and Quality of Life of Patients with Systemic Lupus Erythematosus
Authors: M. Sierakowska, M. Mojsa, E. Iwaniuk, S. Sierakowski, E. Krajewska-Kułak
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic lupus erythematosus - SLE is a chronic autoimmune disease characterized by the involvement of many organs. Fundamental principle of treatment of SLE is a comprehensive and individualized treatment approach, taking into account the duration and severity of the organ damage. Because of systemic, chronic, progressive course SLE adversely affects the physical functioning of patients, as well as it decreases their mental and social condition in effect of QOL lowering. <h3>Objectives</h3> The aim of our work was to identify physical social, and psychological problems in patients suffering from lupus; assessment of quality of life; also to determine the degree of acceptance of the disease. <h3>Methods</h3> The study was conducted among patients with diagnosed, according to the grading criteria of ACR for SLE, on a total of 37 patients. The research method was a diagnostic based on the original questionnaire, Anxiety and Depression Scale - HADS (0-21pts), Acceptance of Illness Scale - AIS (8-40pts), Visual- Analogue Pain Assessment Scale VAS (0-100mm), Quality of Life questionnaire WHOQOL BREF Polish version (4-20pts). <h3>Results</h3> Most health problems which created troubles in the subjective assessment of respondents were: fatigue and weakness (91.9%), arthralgia and myalgia (81%), reduced resistance to illnesses (67.5%). Respondents inactive (1/3 of respondents) felt stronger pain (VAS ≥70mm). Patients with disease duration 0-5 years obtained a greater number of points in the HADS-D scale (mean 6.3) (p≤0.05) and inactive professionals in HADS-A scale (9.2) (p≤0.05). Patients with low education obtained higher value of the HADS-A and HADS-D (p≤0.05). Persons married also received higher scores at HADS-A (8.1) (p≤0.05). Patients with primary education/professional reported the worst acceptance of the disease (AIS - 19.5) (p≤0.05). People diagnosed with the disease at a younger age, single and with short duration of SLE (0-5 years) evaluated their worse functioning in all areas of QOL. The population of respondents with primary education/professional assessed the physical (9.1) and psychological (10.7) realm very low. <h3>Conclusions</h3> The most nagging health problem reported by respondents was fatigue and weakness, joint and muscle pain, and low resistance to illnesses. Pain intensity (VAS) depended on patient9s age and activity. The suspicion of existence of anxiety disorders (HADS-A) was observed more frequently in married and inactive patients. Respondents from all areas rated their physical and mental functioning lowest. Patients with short duration of SLE, alone, as well as with primary education/professional rated lowest their functioning in all areas of QOL. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1374
Abstract 1192: ZMIZ1 is elevated in epithelial ovarian cancer due to an upregulated alternative promoter and is associated with p53 mutations
Authors: Niyati J. Nadkarni, Laura Rogers, Megan Samuelson, Traci Neff, David P. Bender, Amina Ahmed, Koen De Geest, Anna Button, Adam Dupuy, Michael J. Goodheart
Journal: Cancer Research (2012)

Abstract Objectives: The ZMIZ1 gene has recently been found to be a possible, candidate oncogene through a transposon mutagenesis screen. It is widely known that one of the most common genetic alterations in epithelial ovarian cancer involves mutations of the p53 tumor suppressor gene. Previous studies have shown that ZMIZ1 appears to transcriptionally regulate the p53 gene. We hypothesize that ZMIZ1 expression is caused by the presence of an alternative promoter and that the interaction between ZMIZ1 and p53 may impart worse survival. Methods: A retrospective chart review was performed to identify 138 patients with epithelial ovarian cancer. Data collected included clinico-pathologic factors, patient follow-up, and mortality. ZMIZ1 staining and p53 sequencing were performed on all patients. For the determination of ZMIZ1 alternative promoter relative gene expression, RT-PCR was performed on 33 tumors after cDNA had been isolated. Statistical analyses included chi-square analysis and the binomial test. The log rank test was used to evaluate survival analysis. Results: Immunostaining for the ZMIZ1 protein was performed with the following results: 55 (40%) tumors stained positive and 83 (60%) were negative. Of those patients that were found to be ZMIZ1 positive, over half were noted to have a p53 gene mutation. The median survival of the ZMIZ1 positive/p53 mutated cohort was approximately 36 months while the median survival for the ZMIZ1 negative/p53 wild type cohort was 84 months (p = 0.012). ZMIZ1 alternative promoter relative gene expression was noted to be elevated in patients with ZMIZ1 positive immunostaining compared to patients with negative staining. Conclusions: ZMIZ1 staining appears to be present in 40% of patients with epithelial ovarian cancer. In tumors that are ZMIZ1 positive, half contain p53 gene mutations; this combination imparts worse survival. ZMIZ1 upregulation may be due to the presence of a newly identified alternative promoter. Additional studies are ongoing to better define the role of this alternative promoter. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1192. doi:1538-7445.AM2012-1192
TRAINING NON-CARDIOLOGISTS DECREASES MORTALITY DUE TO ST ELEVATION MYOCARDIAL INFARCTION: A PROGRAM FROM THE SOCIETY OF CARDIOLOGY OF SÃO PAULO STATE, BRAZIL
Authors: Luiz A. Machado Cesar, Rui Ramos, Carlos Magalhaes, João Monteiro Ferreira, Bruno M. Mioto, Naide Oliveira, Pedro Farsky, Amaury Amaral, Antonio C.C. Moreno
Journal: Journal of the American College of Cardiology (2016)
ACCUMULATION OF Tc-99m-HMPAO AND Tc-99m-ECD IN RODENT AND HUMAN BREAST TUMOUR CELL LINES IN VITRO
Authors: James R Ballinger, Jill Duncan, H Annie, Masanori Ichise
Journal: Clinical Nuclear Medicine (1998)

Experimental Therapeutics, Ontario Cancer Institute; Nuclear Medicine, Mount Sinai Hospital; and Faculties of Pharmacy and Medicine, University of Toronto, Ontario.
PT-05 * LENNOX GESTAUT SYNDROME PRESENTING AFTER GLIOMA RESECTION - A CASE REPORT
Authors: C. Jacob, N. Dalvi, J. Lajoie
Journal: Neuro-Oncology (2014)

Lennox–Gestaut Syndrome (LGS) is a malignant generalized epilepsy syndrome characterized by a triad of refractory mixed seizure types, mental retardation, and slow spike-and-wave electrographic patterns (mostly 1.5 -2.5 Hz). Uncommonly, low-grade astrocytomas have been described in association with LGS prior to resection. We describe an 11 year old boy who began having seizures in the first year of life and was eventually diagnosed with a low grade astrocytoma at 3 years of age arising from the right temporal region. Electroencephalogram (EEG) before surgery showed bursts of interictal polyspike discharges, with right-sided partial seizures. Pathology revealed a fibrillary astrocytoma. Partial resection was done and he was medically stable on a low dose of a single medication. Seven to eight months postoperatively there was recurrence of seizures and follow up EEG showed a more generalized pattern with background slowing, interictal generalized polyspike discharges and generalized seizures. Clinically seizures were characterized as atonic, atypical absence and generalized tonic-clonic after surgery. Follow up imaging revealed a nodule of enhancement along the surgical cavity, which has been stable for the past few years. In this case there was evolution from partial to generalized seizures, more specifically into a LGS phenotype. Despite lesionectomy of this patient's focal neuro-oncological lesion, there continued to be an ongoing progression of this patient's abnormal neuronal circuitry. Aggressive management of focal lesions with complete lesion resection, antiepileptic medication and follow-up EEG monitoring remains an important aspect of neuro-oncological management.
Diuretic Use and Risk Factors for Cancer: Results of Animal Studies
Authors: JOHN R. BUCHER, JUNE K. DUNNICK
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Diuretic Use and Risk Factors for Cancer: Results of Animal Studies Get access JOHN R. BUCHER, JOHN R. BUCHER Search for other works by this author on: Oxford Academic PubMed Google Scholar JUNE K. DUNNICK JUNE K. DUNNICK Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 15, 5 August 1992, Pages 1209–1210, https://doi.org/10.1093/jnci/84.15.1209 Published: 05 August 1992